Voyager Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $390.71 million
- Book Value:
- Revenue TTM:
- $194.87 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Voyager Therapeutics Inc had its IPO on 2015-11-11 under the ticker symbol VYGR.
The company operates in the Healthcare sector and Biotechnology industry. Voyager Therapeutics Inc has a staff strength of 125 employees.
Shares of Voyager Therapeutics Inc opened at $8.9 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $8.62 - $9.02, and closed at $8.65.
This is a -2.81% slip from the previous day's closing price.
A total volume of 251,792 shares were traded at the close of the day’s session.
In the last one week, shares of Voyager Therapeutics Inc have slipped by -14.36%.
Voyager Therapeutics Inc's Key Ratios
Voyager Therapeutics Inc has a market cap of $390.71 million, indicating a price to book ratio of 2.8246 and a price to sales ratio of 3.2706.
In the last 12-months Voyager Therapeutics Inc’s revenue was $194.87 million with a gross profit of $-19857000 and an EBITDA of $91.67 million. The EBITDA ratio measures Voyager Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Voyager Therapeutics Inc’s operating margin was 44.82% while its return on assets stood at 21.66% with a return of equity of 73.98%.
In Q2, Voyager Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 581.6%.
Voyager Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $2.14 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Voyager Therapeutics Inc’s profitability.
Voyager Therapeutics Inc stock is trading at a EV to sales ratio of 1.6674 and a EV to EBITDA ratio of -8.5632. Its price to sales ratio in the trailing 12-months stood at 3.2706.
Voyager Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $315.54 million
- Total Liabilities
- $45.40 million
- Operating Cash Flow
- Capital Expenditure
- $1.21 million
- Dividend Payout Ratio
Voyager Therapeutics Inc ended 2023 with $315.54 million in total assets and $0 in total liabilities. Its intangible assets were valued at $315.54 million while shareholder equity stood at $199.03 million.
Voyager Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $45.40 million in other current liabilities, 44000.00 in common stock, $-291676000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $244.29 million and cash and short-term investments were $272.75 million. The company’s total short-term debt was $3,013,000 while long-term debt stood at $0.
Voyager Therapeutics Inc’s total current assets stands at $282.18 million while long-term investments were $0 and short-term investments were $28.45 million. Its net receivables were $3.35 million compared to accounts payable of $1.66 million and inventory worth $0.
In 2023, Voyager Therapeutics Inc's operating cash flow was $-24663000.00 while its capital expenditure stood at $1.21 million.
Comparatively, Voyager Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Voyager Therapeutics Inc stock is currently trading at $8.65 per share. It touched a 52-week high of $14.34 and a 52-week low of $14.34. Analysts tracking the stock have a 12-month average target price of $13.67.
Its 50-day moving average was $9.47 and 200-day moving average was $8.8 The short ratio stood at 6.33 indicating a short percent outstanding of 0%.
Around 2071.4% of the company’s stock are held by insiders while 5431.8% are held by institutions.
Frequently Asked Questions About Voyager Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company’s lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer’s disease. It also develops VY-FXN01 to treat Friedreich’s ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson’s disease. In addition, the company develops research program for the treatment of Huntington’s disease. It has collaboration and license agreements with Neurocrine Biosciences, Inc.; Pfizer Inc.; and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.